-

Shareholder Alert: Robbins LLP Announces Beyond Meat, Inc. (BYND) Sued for Misleading Shareholders

SAN DIEGO & EL SEGUNDO, Calif.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of Beyond Meat, Inc. (NYSE: BYND) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between May 2, 2019 and January 27, 2020. Beyond Meat is a food company that provides plant-based meats.

If you suffered a loss as a result of Beyond Meat's misconduct, click here.

Beyond Meat Inc. (BYND) Accused of Breach of Contract and Fraud

According to the complaint, in 2014, Beyond Meat entered into an exclusive supply agreement with Don Lee Farms ("Don Lee") to produce all of Beyond Meat's products. However, in early 2017, Beyond Meat terminated the supply agreement and transferred its production from Don Lee to other food manufacturers. As a result, on May 25, 2017, Don Lee filed a complaint against Beyond Meat alleging breach of contract, misappropriation of trade secrets, and unfair competition. As the litigation proceeded, Don Lee further alleged it found plastics, cardboard, and even a metal nozzle in ingredients that Beyond Meat supplied. Consequently, in March 2019, Don Lee added fraud claims that Beyond Meat had altered a copy of a food-safety audit of its manufacturing facilities and gave it to Don Lee. Beyond Meat consistently denied these claims, however, on January 27, 2020, Don Lee revealed in a press release that a judge had ruled it proved probable validity that Beyond Meat had breached its manufacturing agreement. On this news, Beyond Meat's stock price fell almost 4% to close at $120.12 per share. The stock continues to decline.

Beyond Meat Inc. (BYND) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:BYND

Release Versions
$Cashtags

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Stockholder Alert: Robbins LLP Informs Investors of the Flotek Industries, Inc. (FTK) Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Flotek Industries, Inc. (NYSE: FTK) securities between August 3, 2026 and August 17, 2026 (the "Class Period"). Flotek is an energy technology and services company.The complaint alleges that Flotek misled investors by failing to disclose the cancellation of its $400m Puerto Rican deal.Investors who suffered s...

Robbins LLP Encourages WSE Stockholders with Large Losses to Seek Counsel for the Securities Class Action Lawsuit Against Wise Group plc

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Wise Group plc (NASDAQ: WSE) securities between May 11, 2026 and July 23, 2026 (the "Class Period").The complaint alleges that Wise and certain of its senior executives violated the federal securities laws by making materially false and/or misleading statements regarding the Company's anti-money laundering compliance, a...

Robbins LLP Urges Investors of ARS Pharmaceuticals Inc. to Contact the Firm for Information About the SPRY Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds shareholders that a securities class action has been filed on behalf of all investors who purchased or otherwise acquired ARS Pharmaceuticals Inc. (NASDAQ: SPRY) securities between March 9, 2026 and June 24, 2026 (the "Class Period"). ARS is a clinical stage biopharmaceutical company focused on the development and commercialization of neffy for needle-free intranasal delivery of epinephrine for emergency treatment of Type 1 allergic reactions, incl...
Back to Newsroom